Unknown

Dataset Information

0

Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.


ABSTRACT:

Background

Circulating tumor cell (CTC) counts at baseline and follow-up are an independent prognostic factor in patients receiving standard chemotherapy for non-small cell lung cancer (NSCLC). This study further explored the role of CTCs in EGFR-mutated and ALK-rearranged NSCLC patients administered targeted therapies as first-line treatment.

Methods

CTCs were enumerated with a novel high-efficiency detection method from the blood of 43 patients with EGFR-mutated or ALK-rearranged NSCLC at baseline and at disease-progression. Patients were stratified into favorable and unfavorable groups with baseline CTC counts of < 8 or ? 8 CTCs/3.2 mL, respectively.

Results

A total of 76.7% of the patients were positive for ? 2 CTCs /3.2 ml blood at baseline. The median progression-free survival (PFS) and overall survival (OS) rates of the favorable compared to the unfavorable group were longer (11.6 vs. 8.5 months, P = 0.004 for PFS; 21.00 vs. 17.7 months, P = 0.013 for OS). Multivariate analysis demonstrated that baseline CTC count was a strong predictor of PFS (hazard ratio 2.835; 95% confidence interval 1.240-6.483; P = 0.014) and OS (hazard ratio 3.317; 95% confidence interval 1.360-8.092; P = 0.008).

Conclusion

Baseline CTC count could be a predictive biomarker for EGFR-mutated and ALK-rearranged NSCLCs, which allows for better guidance and monitoring of patients over the course of molecular targeted therapies.

SUBMITTER: Tong B 

PROVIDER: S-EPMC5928386 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.

Tong Bing B   Xu Yan Y   Zhao Jing J   Chen Minjiang M   Zhong Wei W   Xing Jia J   Wang Mengzhao M  

Thoracic cancer 20180327 5


<h4>Background</h4>Circulating tumor cell (CTC) counts at baseline and follow-up are an independent prognostic factor in patients receiving standard chemotherapy for non-small cell lung cancer (NSCLC). This study further explored the role of CTCs in EGFR-mutated and ALK-rearranged NSCLC patients administered targeted therapies as first-line treatment.<h4>Methods</h4>CTCs were enumerated with a novel high-efficiency detection method from the blood of 43 patients with EGFR-mutated or ALK-rearrange  ...[more]

Similar Datasets

| S-EPMC8285416 | biostudies-literature
| S-EPMC4770798 | biostudies-literature
| S-EPMC8651695 | biostudies-literature
| S-EPMC4079055 | biostudies-literature
| S-EPMC7408161 | biostudies-literature
| S-EPMC9879975 | biostudies-literature
| S-EPMC8953392 | biostudies-literature
| S-EPMC7867758 | biostudies-literature
| S-EPMC6343825 | biostudies-literature
| S-EPMC7439864 | biostudies-literature